Abstract Number: 1619 • ACR Convergence 2020
Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center
Background/Purpose: We have noticed an increasing number of serum IgG4 levels ordered over the last several years at our institution. This study was performed to…Abstract Number: 1699 • ACR Convergence 2020
Training Residents to ‘Choose Wisely’ When Testing for Antinuclear Antibodies
Background/Purpose: In many hospitals residents are the first providers to evaluate new patients. Consequently, residents often initiate the work-up of newly admitted patients. Multiple studies…Abstract Number: 1707 • ACR Convergence 2020
Development and Delivery of Continuing Education Interventions Promoting Shared Decision Making in Rheumatoid Arthritis
Background/Purpose: A core CMS policy goal is to improve patient experience by encouraging patient-centered care and shared decision making (SDM). However, SDM techniques are underutilized…Abstract Number: 1723 • ACR Convergence 2020
RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data
Background/Purpose: Flare, relapse from status of treat-to-target (T2T, DAS28< =3.2), is hard predicted. We try to make it predictable by applying machine learning to a…Abstract Number: 1774 • ACR Convergence 2020
Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study
Background/Purpose: Despite guidelines for managing rheumatoid arthritis (RA) in pregnancy, high rates of discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) considered safe for women with RA…Abstract Number: 0244 • ACR Convergence 2020
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?
Background/Purpose: SLE is clinically heterogenous and its diagnosis is often difficult or delayed. The length of time from symptom onset or from when patients seek…Abstract Number: 0535 • ACR Convergence 2020
Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists
Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.Methods: We performed a cross-sectional electronic survey of rheumatologists at…Abstract Number: 0750 • ACR Convergence 2020
Nuclei Detection in Rheumatoid Arthritis Synovial Tissue Using Artificial Intelligence
Background/Purpose: Hematoxylin and eosin (H&E) stained rheumatoid arthritis synovium are routinely used to assess inflammation [1]. In this work, we propose an automated approach using…Abstract Number: 1595 • ACR Convergence 2020
Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making
Background/Purpose: Patient care is moving from physician directed treatment to a co-design framework that focuses on creating a partnership between patients and physicians. This new…Abstract Number: 1597 • ACR Convergence 2020
Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy. …Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…Abstract Number: 411 • 2017 ACR/ARHP Annual Meeting
Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
Background/Purpose: The management plan for rheumatoid arthritis (RA) might be a relatively simple task if only disease activity is considered but might become more complex…Abstract Number: 1045 • 2017 ACR/ARHP Annual Meeting
The Potential Value of a Shared Decision-Making Intervention for Choices Regarding Triple Therapy in Rheumatoid Arthritis
Background/Purpose: Previous studies have shown that using Triple Therapy (a combination of 3 generic drugs) prior to a biologic, is the most cost-effective strategy for…Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting
Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…
ACR Meeting Abstracts